RecruitingPhase 2NCT06848348
Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain
A Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain
Sponsor
Dogwood Therapeutics Inc.
Enrollment
200 participants
Start Date
Feb 21, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
A randomized study to determine safety and efficacy of single subcutaneous (SC) administration of HAL treatment in patients with CINP.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Male or female patients aged ≥18 years.
- Neuropathic pain has been present and is attributed to platinum and/or taxane chemotherapy.
- Patient has received a cancer chemotherapy regimen that included taxanes and/or platinum and has no active or discernible disease progression.
Exclusion Criteria2
- Current neuropathic pain with symptoms similar to CINP but attributed to causes other than platinum or taxane chemotherapy.
- Patients who have received HAL at any time prior to screening.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGHalneuron
Halneuron for Subcutaneous Injection
DRUGPlacebo
Placebo for Subcutaneous Injection
Locations(24)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06848348